S&P 500   3,328.08 (-0.05%)
DOW   29,315.13 (-0.11%)
QQQ   223.71 (+0.15%)
AAPL   318.15 (-0.18%)
FB   221.35 (-0.36%)
MSFT   167.71 (+0.37%)
GOOGL   1,482.52 (+0.20%)
AMZN   1,870.51 (+0.31%)
NVDA   248.74 (-0.22%)
BABA   221.71 (-2.52%)
MU   58.50 (+1.46%)
GE   11.73 (-0.68%)
TSLA   541.67 (+6.10%)
AMD   51.24 (+0.61%)
T   38.45 (+0.16%)
ACB   2.04 (-4.24%)
F   9.17 (+0.00%)
NFLX   337.02 (-0.78%)
BAC   34.50 (-0.61%)
GILD   62.78 (-0.32%)
DIS   143.77 (-0.39%)
S&P 500   3,328.08 (-0.05%)
DOW   29,315.13 (-0.11%)
QQQ   223.71 (+0.15%)
AAPL   318.15 (-0.18%)
FB   221.35 (-0.36%)
MSFT   167.71 (+0.37%)
GOOGL   1,482.52 (+0.20%)
AMZN   1,870.51 (+0.31%)
NVDA   248.74 (-0.22%)
BABA   221.71 (-2.52%)
MU   58.50 (+1.46%)
GE   11.73 (-0.68%)
TSLA   541.67 (+6.10%)
AMD   51.24 (+0.61%)
T   38.45 (+0.16%)
ACB   2.04 (-4.24%)
F   9.17 (+0.00%)
NFLX   337.02 (-0.78%)
BAC   34.50 (-0.61%)
GILD   62.78 (-0.32%)
DIS   143.77 (-0.39%)
S&P 500   3,328.08 (-0.05%)
DOW   29,315.13 (-0.11%)
QQQ   223.71 (+0.15%)
AAPL   318.15 (-0.18%)
FB   221.35 (-0.36%)
MSFT   167.71 (+0.37%)
GOOGL   1,482.52 (+0.20%)
AMZN   1,870.51 (+0.31%)
NVDA   248.74 (-0.22%)
BABA   221.71 (-2.52%)
MU   58.50 (+1.46%)
GE   11.73 (-0.68%)
TSLA   541.67 (+6.10%)
AMD   51.24 (+0.61%)
T   38.45 (+0.16%)
ACB   2.04 (-4.24%)
F   9.17 (+0.00%)
NFLX   337.02 (-0.78%)
BAC   34.50 (-0.61%)
GILD   62.78 (-0.32%)
DIS   143.77 (-0.39%)
S&P 500   3,328.08 (-0.05%)
DOW   29,315.13 (-0.11%)
QQQ   223.71 (+0.15%)
AAPL   318.15 (-0.18%)
FB   221.35 (-0.36%)
MSFT   167.71 (+0.37%)
GOOGL   1,482.52 (+0.20%)
AMZN   1,870.51 (+0.31%)
NVDA   248.74 (-0.22%)
BABA   221.71 (-2.52%)
MU   58.50 (+1.46%)
GE   11.73 (-0.68%)
TSLA   541.67 (+6.10%)
AMD   51.24 (+0.61%)
T   38.45 (+0.16%)
ACB   2.04 (-4.24%)
F   9.17 (+0.00%)
NFLX   337.02 (-0.78%)
BAC   34.50 (-0.61%)
GILD   62.78 (-0.32%)
DIS   143.77 (-0.39%)
Log in
(Ad)
In my 40+ year career, I have yet to see a convergence of three significant factors that has me this optimistic about the stock market. I believe 2020 could deliver the largest wealth-building opportunity in a generation. Don't miss out on this historic year.

NASDAQ:AKAO - Achaogen Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range
$0.11
MA: $0.11
$0.11
52-Week Range N/A
VolumeN/A
Average Volume3.34 million shs
Market Capitalization$7.03 million
P/E RatioN/A
Dividend YieldN/A
Beta0.78
Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKAO
CUSIPN/A
Phone650-800-3636

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.73 million
Book Value($0.13) per share

Profitability

Net Income$-186,510,000.00
Net Margins-2,136.94%

Miscellaneous

Employees206
Market Cap$7.03 million
Next Earnings DateN/A
OptionableOptionable

Receive AKAO News and Ratings via Email

Sign-up to receive the latest news and ratings for AKAO and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


2020 could be a monster year for cannabis stocks, especially with cannabis on many November ballots, and presidential candidates pushing for approval. In our latest special report, we detail five must-own cannabis stocks that could double, even triple your investment over the next year.

Achaogen (NASDAQ:AKAO) Frequently Asked Questions

What is Achaogen's stock symbol?

Achaogen trades on the NASDAQ under the ticker symbol "AKAO."

How were Achaogen's earnings last quarter?

Achaogen Inc (NASDAQ:AKAO) issued its quarterly earnings results on Monday, August, 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.92) by $0.19. The biopharmaceutical company earned $2.56 million during the quarter, compared to analysts' expectations of $1.49 million. Achaogen had a negative return on equity of 357.49% and a negative net margin of 2,136.94%. View Achaogen's Earnings History.

What price target have analysts set for AKAO?

3 brokerages have issued twelve-month target prices for Achaogen's stock. Their forecasts range from $2.00 to $3.00. On average, they anticipate Achaogen's share price to reach $2.50 in the next twelve months. View Analyst Price Targets for Achaogen.

What is the consensus analysts' recommendation for Achaogen?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achaogen in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Achaogen.

What are Wall Street analysts saying about Achaogen stock?

Here are some recent quotes from research analysts about Achaogen stock:
  • 1. According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (4/26/2019)
  • 2. Needham & Company LLC analysts commented, "Achaogen hosted a 4Q18 conference call yesterday to provide a corporate update. Zemdri sales were $0.5M, consistent w/ pre-announced $0.45-0.5M. Mgmt implemented another corporate restructure in Feb 2019 to conserve resources. Sales force and MSL group has been scaled back to only a few personnel who will focus on a modest number of existing accounts. The move is expected to reduce cash burn to $15-17M in 2Q19, pushing runway to Jun 2019. Mgmt continues to examine strategic options, although no details provided. Zemdri is still used primarily in outpatient setting. Given small commercial infrastructure, it seems unlikely the drug will meaningfully penetrate the inpatient hospital setting even as hospitals gradually add the drug to formulary." (3/29/2019)
  • 3. HC Wainwright analysts commented, "916-3963, POS Risk-adj value Full value Rating ZEMDRI – U.S. 100% $1.35 $1.35 Shares outstanding 63,206 S/O: Post-Feb 2019 equity raise. ZEMDRI – EU 35% $0.35 $1.00 Current share price $0.86 Discount rate 24.0% C-Scape – U.S." (2/21/2019)
  • 4. Mizuho analysts commented, "We see significant risk in Achaogen even though we believe ZEMDRI is a positively differentiated product with strategic value. We reduce our 2019 revenue from ~ $27mn to ~$14mn; reiterate Neutral and $3 PT." (2/15/2019)

Has Achaogen been receiving favorable news coverage?

News articles about AKAO stock have trended very positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Achaogen earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Achaogen.

Who are some of Achaogen's key competitors?

What other stocks do shareholders of Achaogen own?

Who are Achaogen's key executives?

Achaogen's management team includes the folowing people:
  • Mr. Blake Wise, CEO & Director (Age 48)
  • Mr. Gary Loeb, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 49)
  • Ms. Zeryn Sarpangal, CFO and Principal Financial & Accounting Officer (Age 39)
  • Ms. Elizabeth Bhatt, Chief Bus. Officer & COO (Age 50)
  • Ms. Jeannie Lloyds, VP of Sales

How big of a company is Achaogen?

Achaogen has a market capitalization of $0.00 and generates $8.73 million in revenue each year. The biopharmaceutical company earns $-186,510,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis. Achaogen employs 206 workers across the globe.View Additional Information About Achaogen.

What is Achaogen's official website?

The official website for Achaogen is http://www.achaogen.com/.

How can I contact Achaogen?

Achaogen's mailing address is 1 TOWER PLACE SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-800-3636 or via email at [email protected]


MarketBeat Community Rating for Achaogen (NASDAQ AKAO)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  456 (Vote Outperform)
Underperform Votes:  272 (Vote Underperform)
Total Votes:  728
MarketBeat's community ratings are surveys of what our community members think about Achaogen and other stocks. Vote "Outperform" if you believe AKAO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKAO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel